Investing in AVITA Medical involves typical risks associated with commercial-stage medical technology and regenerative medicine firms. Key vulnerabilities include execution risks related to expanding sales teams, reliance on clinician adoption of the RECELL system, potential fluctuations in reimbursement coverage from insurance providers, and the necessity of managing operational expenses effectively while driving toward long-term profitability and sustainable cash-flow generation.